Cargando…
A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan
PURPOSE: To evaluate the cost-effectiveness of pregabalin versus other analgesics among patients with chronic cervical pain with neuropathic components during routine clinical practice in Japan. PATIENTS AND METHODS: The analysis considered patients with chronic cervical pain with a neuropathic pain...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765214/ https://www.ncbi.nlm.nih.gov/pubmed/31576163 http://dx.doi.org/10.2147/JPR.S203712 |
_version_ | 1783454523104165888 |
---|---|
author | Akazawa, Manabu Igarashi, Ataru Ebata, Nozomi Murata, Tatsunori Zeniya, Shigeki Haga, Yuri Nozawa, Kazutaka Fujii, Koichi Taguchi, Toshihiko |
author_facet | Akazawa, Manabu Igarashi, Ataru Ebata, Nozomi Murata, Tatsunori Zeniya, Shigeki Haga, Yuri Nozawa, Kazutaka Fujii, Koichi Taguchi, Toshihiko |
author_sort | Akazawa, Manabu |
collection | PubMed |
description | PURPOSE: To evaluate the cost-effectiveness of pregabalin versus other analgesics among patients with chronic cervical pain with neuropathic components during routine clinical practice in Japan. PATIENTS AND METHODS: The analysis considered patients with chronic cervical pain with a neuropathic pain component (radiating pain to the upper limb) and who were treated with pregabalin with or without other analgesics (pregabalin-containing treatments) or other analgesics alone (usual care) for 8 weeks. Other analgesics included non-steroidal anti-inflammatory drugs (NSAIDs), weak opioids, antidepressants, and antiepileptic drugs. A Markov cohort simulation model was constructed to estimate costs and effectiveness (in terms of quality-adjusted life-years, QALYs) of each treatment over a 12-month time horizon. In the model, patients transitioned among three states of pain severity (no/mild, moderate, and severe). Data were derived from a previous observational study (pregabalin-containing treatments, n = 138; usual care, n = 211). Cost inputs included medical costs and productivity losses. QALYs were calculated using the EuroQol five-dimensional, five-level questionnaire. The cost-effectiveness was evaluated using incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were conducted to assess the robustness of results. RESULTS: From the payer’s perspective, pregabalin-containing treatments were more costly (JPY 61,779 versus JPY 26,428) but also more effective (0.763 QALYs versus 0.727 QALYs) than the usual care, with an ICER of JPY 970,314 per QALY gained. From the societal perspective, which also included productivity losses, the ICER reduced to JPY 458,307 per QALY gained. One-way sensitivity analyses demonstrated the robustness of the results. Given a hypothetical threshold value of one additional QALY of JPY 5,000,000, the probability of pregabalin-containing treatments being cost-effective was 100%. CONCLUSION: Compared with using other analgesics alone, the use of pregabalin, alone or in addition to other analgesics, was cost-effective for the treatment of chronic cervical pain with a neuropathic pain component in Japan. |
format | Online Article Text |
id | pubmed-6765214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67652142019-10-01 A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan Akazawa, Manabu Igarashi, Ataru Ebata, Nozomi Murata, Tatsunori Zeniya, Shigeki Haga, Yuri Nozawa, Kazutaka Fujii, Koichi Taguchi, Toshihiko J Pain Res Original Research PURPOSE: To evaluate the cost-effectiveness of pregabalin versus other analgesics among patients with chronic cervical pain with neuropathic components during routine clinical practice in Japan. PATIENTS AND METHODS: The analysis considered patients with chronic cervical pain with a neuropathic pain component (radiating pain to the upper limb) and who were treated with pregabalin with or without other analgesics (pregabalin-containing treatments) or other analgesics alone (usual care) for 8 weeks. Other analgesics included non-steroidal anti-inflammatory drugs (NSAIDs), weak opioids, antidepressants, and antiepileptic drugs. A Markov cohort simulation model was constructed to estimate costs and effectiveness (in terms of quality-adjusted life-years, QALYs) of each treatment over a 12-month time horizon. In the model, patients transitioned among three states of pain severity (no/mild, moderate, and severe). Data were derived from a previous observational study (pregabalin-containing treatments, n = 138; usual care, n = 211). Cost inputs included medical costs and productivity losses. QALYs were calculated using the EuroQol five-dimensional, five-level questionnaire. The cost-effectiveness was evaluated using incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were conducted to assess the robustness of results. RESULTS: From the payer’s perspective, pregabalin-containing treatments were more costly (JPY 61,779 versus JPY 26,428) but also more effective (0.763 QALYs versus 0.727 QALYs) than the usual care, with an ICER of JPY 970,314 per QALY gained. From the societal perspective, which also included productivity losses, the ICER reduced to JPY 458,307 per QALY gained. One-way sensitivity analyses demonstrated the robustness of the results. Given a hypothetical threshold value of one additional QALY of JPY 5,000,000, the probability of pregabalin-containing treatments being cost-effective was 100%. CONCLUSION: Compared with using other analgesics alone, the use of pregabalin, alone or in addition to other analgesics, was cost-effective for the treatment of chronic cervical pain with a neuropathic pain component in Japan. Dove 2019-09-23 /pmc/articles/PMC6765214/ /pubmed/31576163 http://dx.doi.org/10.2147/JPR.S203712 Text en © 2019 Akazawa et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Akazawa, Manabu Igarashi, Ataru Ebata, Nozomi Murata, Tatsunori Zeniya, Shigeki Haga, Yuri Nozawa, Kazutaka Fujii, Koichi Taguchi, Toshihiko A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan |
title | A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan |
title_full | A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan |
title_fullStr | A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan |
title_full_unstemmed | A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan |
title_short | A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan |
title_sort | cost-effectiveness analysis of pregabalin for the treatment of patients with chronic cervical pain with a neuropathic component in japan |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765214/ https://www.ncbi.nlm.nih.gov/pubmed/31576163 http://dx.doi.org/10.2147/JPR.S203712 |
work_keys_str_mv | AT akazawamanabu acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT igarashiataru acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT ebatanozomi acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT muratatatsunori acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT zeniyashigeki acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT hagayuri acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT nozawakazutaka acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT fujiikoichi acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT taguchitoshihiko acosteffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT akazawamanabu costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT igarashiataru costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT ebatanozomi costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT muratatatsunori costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT zeniyashigeki costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT hagayuri costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT nozawakazutaka costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT fujiikoichi costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan AT taguchitoshihiko costeffectivenessanalysisofpregabalinforthetreatmentofpatientswithchroniccervicalpainwithaneuropathiccomponentinjapan |